What Prostadine is intended to support
As a dietary supplement, Prostadine is legally limited to structure/function claims — supporting normal prostate function, urinary flow, bladder comfort and general vitality. It is not approved to treat any condition, and no supplement in this category is.
What the formula contains
Nine disclosed ingredients: four seaweeds (nori, wakame, kelp, bladderwrack), saw palmetto, pomegranate extract, iodine, shilajit and neem. Quantities are not disclosed. The full breakdown is on the ingredients page.
What research exists on the individual ingredients
| Ingredient | Best available human evidence | What it shows |
|---|---|---|
| Saw palmetto | Multiple RCTs including STEP (NEJM 2006) and CAMUS (JAMA 2011); Cochrane reviews | No significant improvement over placebo in symptom scores in the largest trials, even at escalated doses. Earlier smaller trials of specific extracts were more favourable. |
| Pomegranate extract | Small single-arm study and a later randomised placebo-controlled trial in men treated for prostate cancer | Early positive signal on PSA doubling time was not confirmed in the randomised trial. Not a study of urinary symptoms. |
| Shilajit | Small trials on fatigue and male reproductive parameters | Some positive findings, small samples, limited independent replication, not a prostate outcome. |
| Iodine | Extensive nutrient literature | Essential for thyroid hormone synthesis. No established role in treating prostate conditions. |
| Nori, wakame, kelp, bladderwrack, neem | Laboratory and animal studies of isolated compounds | Mechanistic interest only. No human trials for prostate or urinary outcomes identified. |
What the research does not establish
- That the combination of these nine ingredients produces any effect that the individual ingredients do not.
- That the amounts used in Prostadine reach levels studied in any trial — the amounts are not published.
- That a liquid delivery format changes outcomes for these ingredients.
- That any measurable change occurs in prostate size, urinary flow rate, IPSS symptom score, PSA, or night-time urination frequency in people taking this product.
Why ingredient research is not a clinical trial of Prostadine
Manufacturer / product information
Marketing for products in this category typically cites studies on individual ingredients as support for the finished formula.
Research context
In clinical nutrition, outcomes depend on the specific extract, the standardisation, the dose, the dosing schedule, the delivery matrix and the population. Two products containing the same named botanical routinely perform differently, which is one reason saw palmetto trials disagree with each other. Combining nine ingredients also introduces interactions that single-ingredient studies cannot predict.
Editorial takeaway
Citing ingredient studies is a reasonable way to explain why an ingredient was chosen. It is not evidence that the product works. Only a trial of the product itself could show that, and no such trial was identified.
What users should realistically expect
Setting expectations honestly is more useful than a verdict. If you try Prostadine:
- Nothing in the evidence base supports expecting a rapid or dramatic change in urinary symptoms.
- Placebo effects are substantial in urinary symptom trials — placebo arms in BPH studies routinely improve. Feeling better after starting a supplement does not establish that the supplement caused it.
- Any general wellbeing change may come from unrelated factors: hydration, sleep, caffeine and alcohol intake, or simply paying more attention to your health.
- Symptoms that are worsening, or that involve pain, blood or retention, need medical evaluation regardless of what any supplement appears to do.
Editorial conclusion
The evidence does not allow anyone to say Prostadine works, and it does not allow anyone to say it has been shown ineffective either — the study simply has not been done. What can be said is that the strongest ingredient-level evidence in the formula points away from a meaningful effect on urinary symptoms, and that the undisclosed dosing removes the one thing that could have partially closed the gap.
A defensible way to approach it: treat it as an optional wellness purchase with an unproven benefit, buy only within a refund window you are prepared to use, and do not let it delay a clinical assessment of symptoms.
Affiliate link. Check current guarantee terms on the official page before purchasing.
Sources consulted
- Bent S. et al., STEP trial, New England Journal of Medicine 2006
- Barry M.J. et al., CAMUS trial, JAMA 2011
- Tacklind J. et al., Serenoa repens, Cochrane Database
- Paller C.J. et al., pomegranate extract randomised trial, Prostate Cancer and Prostatic Diseases
- NIDDK — Prostate enlargement (benign prostatic hyperplasia)
Product details are recorded as they appeared in the materials we reviewed. Formulas, directions, pricing and guarantee terms can change without notice; always confirm on the current official product page.